Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

Accueil
Investir
ETFs
Etats-Unis
AMEX
Harbor Multi asset Explorer ETF (MAPP) Cours

Harbor Multi asset Explorer ETF (MAPP)

27,3691

-0,7409

(-2,64%)

Fermé 07 Juin 10:00PM

27,37

0,0009

(0,00%)

Après les heures de négociation: 1:59AM

Harbor Multi asset Explorer ETF (MAPP) Action

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Dernier

27,3691

( -2,64% )

Prix Achat

-

Prix Vente

-

Volume échangé

726

27,37 Fourchette du Jour 27,57

23,8561 Plage de 52 semaines 28,275

Clôture Veille

28,11

Ouverture

27,57

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

358

Volume financier

US$ 19 942

VWAP

27,4687

MAP Pharmaceuticals Announces Initiation of LEVADEX(TM) Pharmacokinetics Trial

--Trial to be used in support of NDA submission-- MOUNTAIN VIEW, Calif., Feb. 16 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc...

MAP Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference

MOUNTAIN VIEW, Calif., Jan. 6 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that the company will present at...

MAP Pharmaceuticals Secures $60 Million Committed Equity Financing Facility

MOUNTAIN VIEW, Calif., Nov. 12 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that it has secured a committed...

MAP Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference

MOUNTAIN VIEW, Calif., Nov. 11 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that the company will present...

MAP Pharmaceuticals Completes Interim Safety Review of LEVADEX(TM) Open-Label Safety Extension in More Than 400 Patients

MOUNTAIN VIEW, Calif., Oct. 29 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today announced that it has completed a planned...

MAP Pharmaceuticals' Analysis of Positive Phase 3 LEVADEX(TM) Data To Be Presented in Late-Breaking Session at 14th Congress of

-- Analysis Shows Potential of LEVADEX to Treat a Broad Spectrum of Migraine -- -- Company to Host Webcast on Monday, September 14th at 7:15 a.m...

MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences

- Investor Webcast to Discuss Phase 3 LEVADEX(TM) Data Presented in Late-Breaking Session at the 14th Congress of the International Headache...

MAP Pharmaceuticals Announces Termination of Pediatric Asthma Collaboration

- Company to Suspend Development of UDB - MOUNTAIN VIEW, Calif., July 9 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (NASDAQ:MAPP) today...

MAP Pharmaceuticals Announces Pricing of Its Initial Public Offering

MOUNTAIN VIEW, Calif., Oct. 5 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. announced today that it has priced its initial public offering...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-0.746	-2.65337843365	28.1151	28.275	27.37	406	28.15051	SP
4	-0.6009	-2.14837325706	27.97	28.275	27.37	278	27.99137855	SP
12	0.8591	3.24066390041	26.51	28.275	25.79	358	27.11583028	SP
26	0.5942	2.2192426489	26.7749	28.275	25.4	1060	26.74481015	SP
52	3.513	14.7257934029	23.8561	28.275	23.8561	920	26.48430248	SP
156	7.2291	35.8942403178	20.14	28.275	18.9015	728	23.46257602	SP
260	7.2291	35.8942403178	20.14	28.275	18.9015	728	23.46257602	SP

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Harbor Multi asset Explo...

Global X US 7 to 10 Year...

Bmo Tactical Global Equi...

State Street SPDR S&P Em...

Aveanna Healthcare

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

ADVFN

Vous avez déjà un compte? Connexion

Vous n'avez pas de compte ? Inscription

En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.